The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer.

The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer.

http://www.wikidata.org/entity/Q35399165

about

The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1.Non-small cell lung cancer associated microRNA expression signature: integrated bioinformatics analysis, validation and clinical significance.Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma.Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.AKT Inhibition Promotes Nonautonomous Cancer Cell Survival Regulation of Transient Site-specific Copy Gain by MicroRNA.Versatile roles of extracellular vesicles in cancer Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?Associations of Il-1 Family-Related Polymorphisms With Gastric Cancer Risk and the Role of Mir-197 In Il-1f5 Expression.CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling.Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling.How cancer cells dictate their microenvironment: present roles of extracellular vesicles.Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC.Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance.Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.Two microRNA signatures for malignancy and immune infiltration predict overall survival in advanced epithelial ovarian cancer.An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.New Dancing Couple: PD-L1 and MicroRNA.Prognostic impact of a 3-MicroRNA signature in cytological samples of small cell lung cancer.CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.Micro RNAs mir-106a, mir-122 and mir-197 are increased in severe acute viral hepatitis with coagulopathy.Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.Autophagy inhibition upregulates CD4+ tumor infiltrating lymphocyte expression via miR-155 regulation and TRAIL activation Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway.The small vesicular culprits: the investigation of extracellular vesicles as new targets for cancer treatment.Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy.The relationship between microRNAs and the STAT3-related signaling pathway in cancer.The role of STAT3 in leading the crosstalk between human cancers and the immune system.The Circular RNA Interacts with STAT3, Increasing Its Nuclear Translocation and Wound Repair by Modulating Dnmt3a and miR-17 Function.Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.The MYC oncogene is a global regulator of the immune response.Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.Regulatory interactions between long noncoding RNA LINC00968 and miR-9-3p in non-small cell lung cancer: A bioinformatic analysis based on miRNA microarray, GEO and TCGA.Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.Key questions about the checkpoint blockade-are microRNAs an answer?Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers

P2860

Q26766066-2AB53095-B67A-402E-B1E9-822AE6ED0F09 Q33591618-2EA2B8F9-AE92-436C-B537-2314902F4741 Q33648562-D6C95C9D-100D-40C0-BDEE-BD37049FC532 Q33738859-C244E244-E488-4477-BF85-16FA448F5ED1 Q33784593-4062C778-18B7-45D3-898A-D692038FC425 Q36447471-7D3976EC-9E60-4689-A558-03AABE5F5C25 Q36650250-F7F652E3-F3E3-4F33-A268-D598F78283E5 Q36737955-D8CE1737-AFCC-40C6-9E97-A110C56885DC Q37094056-4D2668AB-5A6B-4686-9005-A9956A0D84B8 Q37328505-1284A0BF-F0E6-493F-90D8-235BB924708E Q37422094-8BCC75D9-1D56-43B0-975E-11C770EE38EF Q37462524-4B4C23F3-EAC5-4976-983F-CD63F0B9198D Q37536748-61453A89-84C7-43EA-A1D4-E7848EA02948 Q37610824-E73A08F4-8CBA-4CC7-9598-FFB9CF116873 Q37675926-2CFF2D5D-B9F8-432E-B721-C11567252FA5 Q38546133-D92581DD-2F11-419F-9B47-75949BD65716 Q38634034-289DF4FB-F761-4974-9EF6-25B3ED336AF9 Q38674837-0BE7B3B4-D1FC-49DE-9C14-818572192189 Q38749945-B52209BB-F246-4944-8DC4-7D368F87B65D Q39108144-7D7EF488-9639-48BA-A326-8507359F0607 Q39413337-EED4F419-C34E-4E86-B11C-967FAEC9CCF7 Q39788725-2069448C-9019-4495-AE91-2FFDC7EE7F1A Q40443884-ECF8830F-6AE0-43FC-A3D9-9D7F624E9862 Q41008618-5CF152FD-0D0A-40A0-8388-D88B54433EB5 Q41367801-F95BB1D5-3E61-4B55-842D-D084C4E8FFAD Q41914210-0C9D8A6F-6057-4CBD-B24D-4C4461CC9548 Q42371619-C9926E59-C419-4B1C-BC07-0E908FD56051 Q44243898-486F3D2C-7BD8-40E2-83D6-2E4FFDEB92D4 Q47128288-41172AA7-6E30-4A2F-ADBB-93926FA6DF17 Q47767814-06C43708-5EC3-4828-A812-180478EA00BA Q47787087-6EF84F4A-C7AE-4C6A-A414-1113090C3DA0 Q49990319-EDE8D607-6347-4BEF-AB91-67BEB6B55FD9 Q50908196-7F465839-1E0A-408C-AF6F-01AF77962E76 Q52630284-0A57DF6D-CE49-4D99-86F0-5654ECF7F801 Q52728139-E1DC4359-E28F-457B-9968-4D24BC44B49A Q52844139-73A0E869-D1DE-47A8-B802-199A4FF1417E Q54977978-D71B0B6F-697E-4500-9470-AEE843C34D25 Q55100565-ABD5DCDE-FCF7-48EC-9AA4-A7F747F524E1 Q55339993-BCF8F155-43E3-4CB7-816F-655994CB9B0C Q56892179-C9899E02-CA4F-4384-B4AF-63287C58FF0F

P2860

The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer.

http://www.wikidata.org/entity/Q35399165

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

The clinical relevance of the ...... nt non-small-cell lung cancer.

@ast

The clinical relevance of the ...... nt non-small-cell lung cancer.

@en

type

label

The clinical relevance of the ...... nt non-small-cell lung cancer.

@ast

The clinical relevance of the ...... nt non-small-cell lung cancer.

@en

prefLabel

The clinical relevance of the ...... nt non-small-cell lung cancer.

@ast

The clinical relevance of the ...... nt non-small-cell lung cancer.

@en

P1433

Q35399165-108CDFCC-4643-4D90-8ED3-12AD9737BE1C

P1476

Q35399165-1C4A243C-E1B0-4B5D-BA16-395C724C5F40

P2093

Q35399165-0301D30D-8313-43D1-BC08-92298E173C6E

Q35399165-0BE4126C-1A03-44B1-B034-6F3FE6DC16C4

Q35399165-2B2C3197-1040-4F86-A487-E834C89BD628

Q35399165-7B7EEEA9-39DA-40BE-B98B-E16EC4EE94D3

Q35399165-9B6AD39F-E6A1-4C9C-BAC4-D0735859FC43

Q35399165-9BC53143-56B6-4D6F-BD03-DCF54CAEA46E

Q35399165-A02E7746-3DFC-4F29-8C0C-80B3CA495717

Q35399165-A194091E-7245-4DA8-B7E7-2E9D297678B8

Q35399165-B0977166-1243-4257-B267-C9E1286D4CA8

Q35399165-B3868614-46B8-49B9-AD8C-59E89F082AAB

P2860

Q35399165-08574FB3-7507-49BD-B7EF-6B25B0A76C82

Q35399165-0C1D5639-E523-4B6B-8CE4-93865785AA0B

Q35399165-1DB10245-7700-48D5-8797-778D4EF164A0

Q35399165-2A97CBAD-5B04-4AC7-8F02-AF0472E27F94

Q35399165-38016182-A00A-441F-84A3-AEF8B9AE6A57

Q35399165-3B5D4654-18AC-4B01-A3AA-EF1E21D6B1ED

Q35399165-498C0CEA-2C7B-4249-95A9-6C8F2962BFC0

Q35399165-4DAF780F-7395-408C-A747-BE2C3B0E1C0B

Q35399165-4FEB09B9-BEED-4ED1-A2A4-5FDA6DA1D2A3

Q35399165-561EF8AE-5328-4ED9-8F42-DAADA420A4A3

P304

Q35399165-CB99773E-6800-4CAF-BADF-812AF6AB648B

P31

Q35399165-C5AF53D9-5F45-430A-A1CF-F78CB16D1756

P356

Q35399165-A89CC28D-D8A0-4159-A14E-90729A862FA0

P433

Q35399165-A42B3AD6-FD8F-402E-BF04-45C87E9D3EF5

P478

Q35399165-51EE0A2A-BC0F-46B4-B968-70F74C3CFA7B

P50

Q35399165-DBEB14E1-FB1F-4C3A-BB69-E4BC04469937

P577

Q35399165-A7D61325-E223-45E7-9CE6-1CB87A154F23

P5875

Q35399165-94C95113-BB45-4098-9117-DDAB9F40635D

P698

Q35399165-B4464439-08C6-4CA0-AC34-7BA75F48E810

P932

Q35399165-9009F646-5A99-4FBF-9769-D27BE0AEAB78

P356

P1433

Molecular Therapy

P1476

The clinical relevance of the ...... nt non-small-cell lung cancer.

@en

P2093

Fumitaka Takeshita

http://www.w3.org/2001/XMLSchema#string

Hiroshi Nokihara

http://www.w3.org/2001/XMLSchema#string

Hisao Asamura

http://www.w3.org/2001/XMLSchema#string

Kazuyoshi Kuwano

http://www.w3.org/2001/XMLSchema#string

Keitaro Hagiwara

http://www.w3.org/2001/XMLSchema#string

Koji Tsuta

http://www.w3.org/2001/XMLSchema#string

Makoto Kawaishi

http://www.w3.org/2001/XMLSchema#string

Nobuyoshi Kosaka

http://www.w3.org/2001/XMLSchema#string

Shigehiro Yagishita

http://www.w3.org/2001/XMLSchema#string

Takahiro Ochiya

http://www.w3.org/2001/XMLSchema#string

P2860

Circulating microRNAs as stable blood-based markers for cancer detection.

Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue.

Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance

Programmed death ligand-1 expression in non-small cell lung cancer.

Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins

P304

717-727

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2015.10

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271130960

http://www.w3.org/2001/XMLSchema#string

P698

25597412

http://www.w3.org/2001/XMLSchema#string

P932

4395779

http://www.w3.org/2001/XMLSchema#string